

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Innovative Pharmaceutical Biotech Limited, you should at once hand this circular and the accompanying proxy form to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

- (1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE SHARES
AND TO BUY BACK SHARES;
(2) RE-ELECTION OF DIRECTORS; AND
(3) NOTICE OF ANNUAL GENERAL MEETING**
-

A letter from the Board is set out on pages 3 to 6 of this circular. A notice convening the Annual General Meeting to be held at Falcon Room I, Basement, Gloucester Luk Kwok Hong Kong, 72 Gloucester Road, Wanchai, Hong Kong on Monday, 31 August 2020 at 11:00 a.m. (or any adjournment thereof) is enclosed with this circular.

A form of proxy for the Annual General Meeting is also enclosed with this circular. Whether or not you intend to attend the Annual General Meeting in person, please complete, sign and return the form of proxy in accordance with the instructions printed thereon to the Company's branch share registrar and transfer agent in Hong Kong, Tricor Tengis Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, as soon as possible and in any event not less than 48 hours before the time appointed for holding of the Annual General Meeting or any adjournment thereof. Completion and return of the form of proxy will not preclude you from attending and voting at the Annual General Meeting or any adjourned meeting thereof in person should you so wish and in such event, the form of proxy shall be deemed to be revoked.

31 July 2020

CONTENTS

	<i>Pages</i>
Definitions	1
Letter from the Board	
1. Introduction	3
2. General mandates to issue and buy back Shares	4
3. Re-election of Directors.....	5
4. Annual General Meeting.	5
5. Responsibility statement.....	6
6. Recommendation	6
7. General information	6
Appendix I — Explanatory statement	I-1
Appendix II — Biographies of Directors proposed for re-election	II-1
Notice of Annual General Meeting	N-1

DEFINITIONS


In this circular, unless the context otherwise requires, the expressions below shall have the following meanings:

“Annual General Meeting”	the annual general meeting of the Company to be held on Monday, 31 August 2020 at 11:00 a.m. at Falcon Room I, Basement, Gloucester Luk Kwok Hong Kong, 72 Gloucester Road, Wanchai, Hong Kong to consider and, if thought fit, approve, among other things, the grant of the general mandates to issue Shares and to buy back Shares and the proposed re-election of Directors
“associate(s)”	has the same meaning ascribed to it under the Listing Rules
“Board”	the board of Directors
“Buy-back Mandate”	has the meaning set forth in the paragraph headed “2. GENERAL MANDATES TO ISSUE AND BUY BACK SHARES” in the section headed “Letter from the Board”
“Bye-laws”	the bye-laws of the Company
“Company”	Innovative Pharmaceutical Biotech Limited (領航醫藥及生物科技有限公司), a company incorporated in the Cayman Islands and continued in Bermuda with limited liability and the issued Shares of which are listed on the main board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“Extended Mandate”	has the meaning set forth in the paragraph headed “2. GENERAL MANDATES TO ISSUE AND BUY BACK SHARES” in the section headed “Letter from the Board”
“Group”	the Company and its subsidiaries
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China

DEFINITIONS

“Latest Practicable Date”	Friday, 24 July 2020, being the latest practicable date prior to the printing of this circular for ascertaining certain information for inclusion in this circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Share(s)”	share(s) of HK\$0.01 each in the share capital of the Company
“Share Issue Mandate”	has the meaning set forth in the paragraph headed “2. GENERAL MANDATES TO ISSUE AND BUY BACK SHARES” in the section headed “Letter from the Board”
“Shareholder(s)”	registered holder(s) of the Shares
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Takeovers Code”	the Code on Takeovers and Mergers issued by the Securities and Futures Commission of Hong Kong
“%”	per cent.

LETTER FROM THE BOARD



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)
(Stock Code: 399)

Executive Directors:

Mr. Gao Yuan Xing
Mr. Tang Rong
Ms. Huang He

Non-executive Directors:

Ms. Jiang Nian (Chairman)
Ms. Xiao Yan
Ms. Wu Yanmin

Independent non-executive Directors:

Ms. Chen Weijun
Dr. Zhang Zhihong
Mr. Wang Rongliang

Registered Office:

Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Principal Place of

Business in Hong Kong:
Unit No. 2111, 21/F
West Tower Shun Tak Centre
Nos. 168-200
Connaught Road Central
Sheung Wan
Hong Kong

31 July 2020

To the Shareholder(s),

Dear Sir or Madam,

**(1) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE SHARES
AND TO BUY BACK SHARES;
(2) RE-ELECTION OF DIRECTORS; AND
(3) NOTICE OF ANNUAL GENERAL MEETING**

1. INTRODUCTION

The purpose of this circular is to give you information regarding the ordinary resolutions to be proposed at the Annual General Meeting to enable the Shareholders to make an informed decision on whether to vote for or against the resolutions, and the notice of the Annual General Meeting.

LETTER FROM THE BOARD

The resolutions to be proposed at the Annual General Meeting include, inter alia, (i) the grant of general mandates to issue Shares and to buy back Shares; and (ii) the re-election of Directors.

2. GENERAL MANDATES TO ISSUE AND BUY BACK SHARES

At the last annual general meeting of the Company held on 28 August 2019, ordinary resolutions were passed granting general mandates to the Directors to exercise the powers of the Company to issue Shares and to buy back Shares. Such general mandates will expire at the conclusion of the Annual General Meeting.

At the Annual General Meeting, the following ordinary resolutions relating to the granting to the Directors the new and unconditional mandates to exercise the powers of the Company to issue Shares and to buy back Shares will be proposed:

- (i) to allot, issue and deal with new Shares up to an amount not exceeding 20% of the total number of Shares in issue as at the date of passing of relevant resolutions by the Shareholders (the “Share Issue Mandate”). The granting of the Share Issue Mandate will provide the Directors the flexibility to issue Shares when it is in the interest of the Company;
- (ii) to buy back the Shares on the Stock Exchange representing up to a maximum amount of 10% of the total number of Shares in issue as at the date of passing of relevant resolutions by the Shareholders (the “Buy-back Mandate”); and
- (iii) subject to the above two proposed ordinary resolutions being passed, to include the total number of Shares which may from time to time be bought back by the Company pursuant to the Buy-back Mandate to the Share Issue Mandate (the “Extended Mandate”).

The above resolutions, once passed, will empower the Directors to exercise such authority during the period up to: (1) the conclusion of the next annual general meeting of the Company; or (2) the expiration of the period within which the next annual general meeting of the Company is required by the applicable laws of the Bermuda or the Bye-laws to be held; or (3) the date of revocation or variation of the said resolutions by passing an ordinary resolution in general meeting prior to the next annual general meeting, whichever is the earliest.

As at the Latest Practicable Date, there were in issue an aggregate of 1,464,193,024 Shares. Assuming that no further Shares will be issued or bought back prior to the Annual General Meeting, (i) if the Share Issue Mandate is exercised in full, the maximum number of Shares which

LETTER FROM THE BOARD

may be allotted and issued by the Company will be 292,838,604 Shares; and (ii) if the Buy-back Mandate is exercised in full, the maximum number of Shares which may be bought back by the Company will be 146,419,302 Shares.

An explanatory statement in connection with the Buy-back Mandate is set out in Appendix I to this circular. The explanatory statement contains all the requisite information required under the Listing Rules to be given to the Shareholders to enable them to make an informed decision as to whether to vote for or against the relevant resolution.

3. RE-ELECTION OF DIRECTORS

In accordance with Bye-law 84(1) of the Bye-laws, Mr. Tang Rong (“Mr. Tang”), Dr. Zhang Zhihong (“Dr. Zhang”) and Ms. Huang He (“Ms. Huang”) will retire by rotation at the Annual General Meeting. Mr. Tang, Dr. Zhang and Ms. Huang, being eligible, will offer themselves for re-election at the Annual General Meeting.

Ordinary resolutions to re-elect each of Mr. Tang, Dr. Zhang and Ms. Huang as Directors will be proposed at the Annual General Meeting.

Biographical details of Ms. Jiang, Mr. Tang, Dr. Zhang and Ms. Huang are set out in Appendix II to this circular.

4. ANNUAL GENERAL MEETING

The notice convening the Annual General Meeting to be held at Falcon Room I, Basement, Gloucester Luk Kwok Hong Kong, 72 Gloucester Road, Wanchai, Hong Kong on Monday, 31 August 2020 at 11:00 a.m. is set out on pages N-1 to N-6 of this circular. Ordinary resolutions will be proposed at the Annual General Meeting to approve, among other things, the grant of Share Issue Mandate (including the Extended Mandate) and the Buy-back Mandate, and the re-election of Directors.

A form of proxy for the Annual General Meeting is also enclosed with this circular. Whether or not you intend to attend the Annual General Meeting, you are requested to complete and return the form of proxy to the Company’s branch share registrar and transfer agent in Hong Kong, Tricor Tengis Limited, at Level 54, Hopewell Centre, 183 Queen’s Road East, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for holding the Annual General Meeting or any adjournment thereof. The completion and return of the form of proxy will not preclude you from attending and voting at the Annual General Meeting or any adjourned meeting thereof in person should you so wish and in such event, the form of proxy shall be deemed to be revoked.

LETTER FROM THE BOARD

Pursuant to Rule 13.39(4) of the Listing Rules, any vote of the Shareholders at the Annual General Meeting must be taken by poll. An announcement on the poll results will be published by the Company on the date of the Annual General Meeting in the manner as prescribed under Rule 13.39(5) of the Listing Rules.

5. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquires, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

6. RECOMMENDATION

The Directors believe that (i) the granting to the Directors of the Share Issue Mandate (including the Extended Mandate) and the Buy-back Mandate; and (ii) the re-election of Directors are in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend that all Shareholders vote in favour of the ordinary resolutions to be proposed at the Annual General Meeting.

7. GENERAL INFORMATION

To the best of the Directors' knowledge, information and belief, having made all reasonable enquires, no Shareholder is required to abstain from voting on the resolutions to be proposed at the Annual General Meeting.

Your attention is drawn to the additional information set out in the appendices to this circular.

Yours faithfully,

By order of the Board

Innovative Pharmaceutical Biotech Limited

Jiang Nian

Chairman

This is an explanatory statement given to all Shareholders relating to a resolution to be proposed at the Annual General Meeting for approving the Buy-back Mandate. This explanatory statement contains all the information required pursuant to Rule 10.06(1)(b) and other relevant provisions of the Listing Rules which are set out as follows:

1. SHARES IN ISSUE

As at the Latest Practicable Date, there were a total of 1,464,193,024 Shares in issue.

Subject to the passing of the resolution granting the Buy-back Mandate, exercise in full of the Buy-back Mandate, on the basis that no further Shares will be issued or bought back prior to the date of the Annual General Meeting, could accordingly result in up to 146,419,302 Shares, representing approximately 10% of the entire issued share capital of the Company as at the date of passing of the resolution, being bought back by the Company.

2. REASONS FOR BUY BACK

The Directors believe that it is in the best interests of the Company and its Shareholders to seek a general authority from Shareholders to enable the Directors to buy back the Shares in the market. Such buy-backs may, depending on market conditions and funding arrangements at the material time, lead to an enhancement of the net value of the Shares and/or its earnings per Share and will only be made when the Directors believe that such buy-backs will benefit the Company and the Shareholders as a whole.

3. FUNDING OF BUY BACK

Pursuant to the Buy-back Mandate, buy-backs would be funded out of funds legally available in accordance with the provisions of the Bye-laws, the laws of Bermuda, the Listing Rules and for such purpose.

On the basis of the consolidated financial position of the Company as at 31 March 2020 (being the date to which the latest published audited financial statements of the Company have been made up), the Directors consider that the exercise in full of the Buy-back Mandate to buy back Shares at any time during the proposed buy-back period may potentially have a material adverse impact on the working capital or gearing position of the Company as compared with its financial position as at 31 March 2020. The Directors do not propose to make any buy back to the extent that it would, in the circumstances, have a material adverse impact on the working capital or gearing position of the Company which, in the opinion of the Directors, is from time to time appropriate for the Company.

4. SHARE PRICES

The highest and lowest market prices at which the Shares were traded on the Stock Exchange in each of the previous twelve calendar months (up to the Latest Practicable Date) are as follows:

Month	Price per Share	
	Highest	Lowest
	<i>HK\$</i>	<i>HK\$</i>
2019		
July	0.355	0.340
August	0.360	0.295
September	0.330	0.305
October	0.330	0.310
November	0.350	0.280
December	0.310	0.250
2020		
January	0.410	0.245
February	0.285	0.247
March	0.265	0.233
April	0.260	0.230
May	0.260	0.230
June	0.255	0.203
July (up to the Latest Practicable Date)	0.250	0.225

5. BUY BACKS OF SHARES MADE BY THE COMPANY

No buy backs of Shares have been made by the Company (whether on the Stock Exchange or otherwise) during the last six months preceding the Latest Practicable Date.

6. UNDERTAKING OF DIRECTORS

To the best of their knowledge, having made all reasonable enquiries, none of the Directors nor any of their close associates (as defined in the Listing Rules) has any intention, if the Buy-back Mandate is approved by the Shareholders, to sell any Shares to the Company or its subsidiaries.

No other core connected persons (as defined in the Listing Rules) of the Company have notified the Company that they have a present intention to sell the Shares to the Company, or have undertaken not to do so, if the Buy-back Mandate is approved by the Shareholders.

The Directors have undertaken to the Stock Exchange, so far as the same may be applicable, to exercise the powers of the Company to buy back the Shares pursuant to the Buy-back Mandate in accordance with the Listing Rules and the applicable laws of Bermuda.

7. TAKEOVERS CODE AND PUBLIC FLOAT REQUIREMENT

If as a result of a share buy back pursuant to the Buy-back Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning of the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with rule 26 of the Takeovers Code.

As at the Latest Practicable Date, Dr. Mao Yumin ("Dr. Mao") and together with his associates was interested in 377,151,350 Shares, representing approximately 25.76% of the issued share capital of the Company. Based on such shareholdings, in the event that the Directors exercise in full the power to repurchase the Shares pursuant to the Repurchase Mandate and that there is no change in the issued share capital of the Company after the Latest Practicable Date, the shareholdings of Dr. Mao and together with his associates would increase to approximately 28.62% of the issued share capital of the Company. In the event that any exercise of the Repurchase Mandate would, to the Directors' knowledge, have such a consequence, the Directors would not exercise the Repurchase Mandate to such extent. Apart from Dr. Mao and his associates, the Directors are not aware of any other Shareholder or group of Shareholders acting in concert who will become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code as a result of repurchase of the Shares.

Assuming that there is no further issue or buy back of the Shares between the Latest Practicable Date and the date of buy back, the exercise of the Buy-back Mandate whether in whole or in substantial part may result in less than 25% of the issued share capital of the Company being held by the public as required under Rule 8.08 of the Listing Rules. The Directors, however, have no present intention to exercise the Buy-back Mandate to an extent as may result in a public shareholding of less than such prescribed percentage.

APPENDIX II BIOGRAPHIES OF DIRECTORS PROPOSED FOR RE-ELECTION

The following are the particulars of the Directors proposed to be re-elected at the Annual General Meeting.

MR. TANG RONG

Mr. Tang Rong (“Mr. Tang”), aged 53, has been appointed as an executive director with effect from 29 September 2014. Mr. Tang graduated from Fudan University in the People’s Republic of China in July 1989 with a bachelor’s degree in science, majoring in genetics and genetic engineering. He has been an engineer of The Institute of Genetics of Fudan University from November 1989 and has extensive experience in genetics related technology development, commercialization and market development. Mr. Tang successfully filed several patents in China and published papers in many science magazines in genetics related subjects. He was invited as the member of the Committee of Experts of 上海聯眾基因科技研究院 (Shanghai Lianzhong Institute of Gene Technology) in 2000. Starting from November 2010, Mr. Tang was appointed as the director of Gene Testing Research and Development Department of Longmark (Shanghai) Healthcare Limited and he has professional expertise in gene testing and research and development.

Save as disclosed above, Mr. Tang did not hold any directorship in the past three years in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

As at the Latest Practicable Date, Mr. Tang held 396,200 Shares. Save as disclosed above, Mr. Tang was not interested or deemed to have any interest or short position in the shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the SFO.

Mr. Tang does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company.

There is no service contract entered into between the Company and Mr. Tang and his appointment has no specific term. His appointment is subject to retirement by rotation at least once every three years in accordance with the provisions of the Bye-laws. Subject to review by the remuneration committee of the Company from time to time, Mr. Tang is entitled to a director’s remuneration of HK\$37,500 per month and annual director’s fee of HK\$60,000, which was determined by the Board with reference to duties and responsibilities in the Group.

Mr. Tang has confirmed that save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no other matters in respect of his appointment that need to be brought to the attention of the Shareholders.

APPENDIX II BIOGRAPHIES OF DIRECTORS PROPOSED FOR RE-ELECTION

DR. ZHANG ZHIHONG

Dr. Zhang Zhihong (“Dr. Zhang”), aged 80, has been appointed as an independent non-executive director with effect from 8 June 2011 and is a member of the audit committee, the remuneration committee and the nomination committee of the Company. Dr. Zhang graduated from Fudan University majoring in biophysics in 1963 and obtained a doctorate degree in science from Kyoto University, Japan in 1988. From 1990 to 1991, Dr. Zhang was a senior visiting fellow at the medical school of Harvard University in the United States of America. From 1986 to 2000, Dr. Zhang undertook various senior positions at Fudan University, including the officer of the Department of Physiology and Biophysics and the associate dean of the School of Life Sciences. Dr. Zhang was the deputy chairman of the Biophysical Society of China from 1994 to 2002 and the chairman of the Shanghai Society of Biophysics from 2000 to 2008. Dr. Zhang has extensive knowledge and is highly regarded in the field of biophysics and physiology in China.

Save as disclosed above, Dr. Zhang did not hold any directorship in the past three years in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

As at the Latest Practicable Date, Dr. Zhang was not interested or deemed to have any interest or short position in the shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the SFO.

Dr. Zhang does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company.

There is no service contract entered into between the Company and Dr. Zhang and his appointment has no specific term. His appointment is subject to retirement by rotation at least once every three years in accordance with the provisions of the Bye-laws. Subject to review by the remuneration committee of the Company from time to time, Dr. Zhang is entitled to receive an annual director’s fee of HK\$60,000 which was determined by the Board with reference to her duties and responsibilities in the Company.

Dr. Zhang has confirmed that save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no other matters in respect of his appointment that need to be brought to the attention of the Shareholders.

MS. HUANG HE

Ms. Huang He (“Ms. Huang”), aged 38, has been appointed as an executive director with effect from 10 January 2017. Ms. Huang has over 10 years of experience in corporate and investment management as well as mergers and acquisitions in the PRC. From 13 October 2016 to 20 December 2016, Ms. Huang was the executive director of Kong Shum Union Property Management (Holding) Limited, a company listed on the Growth Enterprise Market of the Stock Exchange. Ms. Huang is currently the legal representative and chairman of several companies that were incorporated in the PRC. From 7 August 2015 to 20 February 2017, Ms. Huang was also the executive director of China Ocean Fishing Holdings Limited whose shares are listed on the GEM of the Stock Exchange.

Save as disclosed above, Ms. Huang did not hold any directorship in the past three years in other public companies, the securities of which are listed on any securities market in Hong Kong or overseas.

As at the Latest Practicable Date, Ms. Huang was not interested or deemed to have any interest or short position in the shares, underlying shares or debentures of the Company or its associated corporations within the meaning of Part XV of the SFO.

Ms. Huang does not have any relationship with any directors, senior management, substantial shareholders or controlling shareholders (as defined in the Listing Rules) of the Company.

There is no service contract entered into between the Company and Ms. Huang and her appointment has no specific term. Her appointment is subject to retirement by rotation at least once every three years in accordance with the provisions of the Bye-laws. Subject to review by the remuneration committee of the Company from time to time, Ms. Huang is entitled to receive a director’s remuneration of HK\$50,000 per month which was determined by the Board with reference to her duties and responsibilities in the Company.

Ms. Huang has confirmed that save as disclosed above, there is no other information that needs to be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no other matters in respect of her appointment that need to be brought to the attention of the Shareholders.

NOTICE OF ANNUAL GENERAL MEETING



INNOVATIVE PHARMACEUTICAL BIOTECH LIMITED

領航醫藥及生物科技有限公司

(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)

(Stock Code: 399)

NOTICE IS HEREBY GIVEN that an annual general meeting of Innovative Pharmaceutical Biotech Limited (the “Company”) will be held at Falcon Room I, Basement, Gloucester Luk Kwok Hong Kong, 72 Gloucester Road, Wanchai, Hong Kong on Monday, 31 August 2020 at 11:00 a.m. for the following purposes:

AS ORDINARY BUSINESS

1. To receive and adopt the audited financial statements and the reports of the directors (the “Director(s)”) and of the auditors (the “Auditors”) of the Company for the year ended 31 March 2020.
2.
 - (i) To re-elect Mr. Tang Rong as an executive Director;
 - (ii) To re-elect Dr. Zhang Zhihong as an independent non-executive Director;
 - (iii) To re-elect Ms. Huang He as an executive Director; and
 - (iv) To authorise the board of Directors (the “Board”) to fix the Directors’ remuneration.
3. To re-appoint Elite Partners CPA Limited as the Auditors and to authorise the Board to fix their remuneration.

NOTICE OF ANNUAL GENERAL MEETING

AS SPECIAL BUSINESS

4. To consider and, if thought fit, pass with or without amendments, the following resolutions as an ordinary resolution:

“THAT

- (a) subject to paragraph (c) of this resolution, the exercise by the Directors during the Relevant Period (as defined in paragraph (d) below) of all the powers of the Company to allot, issue and otherwise deal with additional shares (“Shares”) in the share capital of the Company or securities convertible into the Shares, or options, warrants or similar rights to subscribe for any Shares or such convertible securities, and to make, grant, sign or execute offers, agreements or options, deeds and other documents which would or might require the exercise of such powers, subject to and in accordance with all applicable laws, be and is hereby generally and unconditionally approved;
- (b) the approval in paragraph (a) of this resolution shall authorise the Directors during the Relevant Period to make, grant, sign or execute offers, agreements or options, deeds and other documents which would or might require the exercise of such powers after the end of the Relevant Period;
- (c) the total number of shares of the Company allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to an option or otherwise) and issued by the Directors pursuant to the approval in paragraph (a) of this resolution, otherwise than pursuant to:
 - (i) a Rights Issue (as defined in paragraph (d) below); or
 - (ii) any issue of the Shares upon the exercise of rights of subscription or conversion attaching to any warrants of the Company or any securities which are convertible into the Shares; or
 - (iii) the exercise of any option under any share option scheme of the Company or similar arrangement for the time being adopted or rights to acquire the Shares; or

NOTICE OF ANNUAL GENERAL MEETING

(iv) any issue of the Shares as scrip dividends or under similar arrangement providing for the allotment of the Shares in lieu of the whole or part of a dividend on the Shares in accordance with the bye-laws of the Company in force from time to time; or

(v) a specific authority granted by the shareholders of the Company.

shall not exceed 20 per cent. of the total number of the shares of the Company in issue as at the date of passing of this resolution, and the said approval shall be limited accordingly;

(d) for the purpose of this resolution:

“Relevant Period” means the period from the passing of this resolution until whichever is the earliest of:

(i) the conclusion of the next annual general meeting of the Company; or

(ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or the applicable laws of Bermuda to be held; or

(iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting prior to the next annual general meeting of the Company; and

“Rights Issue” means an allotment, issue or grant of the Shares pursuant to an offer of the Shares open for a period fixed by the Directors to the holders of the Shares whose names appear on the register of members of the Company on a fixed record date in proportion to their then holdings of such Shares as at that date (subject to such exclusions or other arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements or having regard to any restrictions or obligations under the laws of, or the requirements of any recognised regulatory body or any stock exchange in, any territory applicable to the Company).”

NOTICE OF ANNUAL GENERAL MEETING

5. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“THAT

- (a) subject to paragraph (b) of this resolution, the exercise by the Directors during the Relevant Period (as defined below) of all powers of the Company to purchase Shares in the share capital of the Company or securities convertible into the Shares on The Stock Exchange of Hong Kong Limited (“Stock Exchange”) or on any other exchange on which the securities of the Company may be listed and recognised by the Securities and Futures Commission of Hong Kong and the Stock Exchange for this purpose (“Recognised Stock Exchange”), subject to and in accordance with the applicable laws of Bermuda and the requirements of the Rules Governing the Listing of Securities on the Stock Exchange or those of any other Recognised Stock Exchange as amended from time to time, be and the same is hereby generally and unconditionally approved;
- (b) the total number of the Shares and securities convertible into the Shares which may be bought back by the Company pursuant to the approval in paragraph (a) of this resolution during the Relevant Period shall not exceed 10 per cent. of the total number of the shares of the Company in issue as at the date of passing of this resolution, and the approval pursuant to paragraph (a) of this resolution shall be limited accordingly;
- (c) for the purpose of this resolution, “Relevant Period” means the period from the date of passing of this resolution until whichever is the earliest of:
 - (i) the conclusion of the next annual general meeting of the Company; or
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the bye-laws of the Company or the applicable laws of Bermuda to be held; or
 - (iii) the date on which the authority set out in this resolution is revoked or varied by an ordinary resolution of the shareholders of the Company in general meeting prior to the next annual general meeting of the Company.”

NOTICE OF ANNUAL GENERAL MEETING

6. To consider and, if thought fit, pass with or without amendments, the following resolution as an ordinary resolution:

“**THAT** subject to the passing of the resolutions numbered 4 and 5 above, the general mandate granted to the Directors to exercise the powers of the Company to allot, issue and otherwise deal with the share capital of the Company pursuant to the resolution numbered 4 be and the same is hereby extended by the addition to the total number of Shares which may be allotted or agreed conditionally or unconditionally to be allotted by the Directors pursuant to such general mandate of an amount representing the total number of Shares bought back by the Company pursuant to the resolution numbered 5 provided that such amount shall not exceed 10 per cent of the total number of Shares in issue as at the date of passing of this resolution.”

By order of the Board
Innovative Pharmaceutical Biotech Limited
Jiang Nian
Chairman

Hong Kong, 31 July 2020

Registered Office:
Clarendon House
2 Church Street
Hamilton HM 11
Bermuda

Principal Place of Business in Hong Kong:
Unit No. 2111, 21/F
West Tower Shun Tak Centre
Nos. 168-200
Connaught Road Central
Sheung Wan
Hong Kong

NOTICE OF ANNUAL GENERAL MEETING

Notes:

- (1) A member of the Company entitled to attend and vote at the aforesaid meeting is entitled to appoint one or (if holding two or more Shares) more proxies to attend and vote in his stead. A proxy need not be a member of the Company. If more than one proxy is appointed, the appointment shall specify the number and class of Shares in respect of which each such proxy is so appointed.
- (2) To be valid, the form of proxy together with any power of attorney or other authority under which it is signed or a notarially certified copy of that power of attorney or other authority must be deposited with the branch share registrar and transfer agent of the Company in Hong Kong, Tricor Tengis Limited at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, not later than 48 hours before the time fixed for holding the meeting or any adjournment thereof.
- (3) When there are joint holders of any Shares, any one of such persons may vote at the meeting either personally or by proxy in respect of such Share as if he were solely entitled thereto; but if more than one of such joint holders are present at the meeting jointly or by proxy, then one of the said persons so present whose name stands first on the register of members of the Company shall alone be entitled to vote in respect of such Share.
- (4) Completion and return of the form of proxy will not preclude members from attending and voting at the aforesaid meeting and in such event, the form of proxy shall be deemed to be revoked.
- (5) For determining the entitlement to attend and vote at the annual general meeting of the Company, the register of members of the Company will be closed from 26 August 2020, Wednesday to 31 August 2020, Monday, both days inclusive, during which period no transfer of Shares will be registered. All transfers of Shares accompanied by the relevant share certificates and properly completed transfer forms must be lodged with the branch share registrar and transfer agent of the Company in Hong Kong, Tricor Tengis Limited, at Level 54, Hopewell Centre, 183 Queen's Road East, Hong Kong, not later than 4:30 p.m. on 25 August 2020.

As at the date of this notice, the Board comprises Ms. Jiang Nian (chairman & non-executive Director), Mr. Gao Yuan Xing (executive Director), Mr. Tang Rong (executive Director), Ms. Huang He (executive Director), Ms. Xiao Yan (non-executive Director), Ms. Wu Yanmin (non-executive Director), Ms. Chen Weijun (independent non-executive Director), Dr. Zhang Zhihong (independent non-executive Director) and Mr. Wang Rongliang (independent non-executive Director).